Flexion patient dosing underway in lead product study • 4:27 PM
Douglas W. House, SA News Ed...
The first patient has been dosed in a 450-patient Phase 3 clinical trial assessing Flexion Therapeutics' (NASDAQ:FLXN) lead product candidate, FX006, for the treatment of moderate-to-severe pain associated with osteoarthritis of the knee.
FX006 is a novel, non-opioid, sustained release, intra-articular formulation of triamcinolone acetonide. The company expects top line data in 2016.
The FDA lifted its clinical hold on the company's Phase 2b trial in early December after it concluded its investigation of a case of septic shock in one patient.
Check out AMPE for possible similar jump as NRX today. Have 3 drugs in pipeline. Had good initial trial results for Ampion to address arthritis of the knee - and even promote cartilage regeneration. Ran up to $10.86 on results; then announce the carrier blew the temp control, so redoing some part of study. They are so confident of approval they built a factory and are ready to produce. But major selloff sue to lack of confidence in mgmt. Do your own research.